CFP
HOME HELP CONTACT US FEEDBACK SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES SEARCH
QUICK SEARCH:   [advanced]


     

Can Fam Physician
Vol. 54, No. 7, July 2008, pp.988 - 992
Copyright © 2008 by The College of Family Physicians of Canada
This Article
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frank, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frank, C.

Case Report

Recognition and treatment of serotonin syndrome

Christopher Frank, MD FCFP
Assistant Professor in the Department of Medicine at Queen’s University in Kingston, Ont. He is attending physician at St Mary’s of the Lake Hospital in Kingston

Correspondence to: Dr Frank, St Mary’s of the Lake Hospital, Division of Geriatric Medicine, 340 Union St, Kingston, ON K7L 5A2; telephone 613 548-7222, extension 2208; fax 613 544-4017; e-mailfrankc{at}providencecare.ca

Serotonin syndrome is an increasingly common adverse drug reaction, which can be life-threatening.1 Despite the common use of medications with direct or indirect serotonergic effects, many physicians are not aware of the presentation and management of serotonin excess.2 This is particularly true of less severe presentations of serotonin syndrome, which still contribute to patient morbidity.3

Family physicians need to be more aware of serotonin syndrome. This case report explains the syndrome’s pathogenesis, diagnosis, and management. Physicians are encouraged to consider the possibility of serotonin syndrome in patients who use serotonergic medications and present with autonomic changes, mental status changes, and neurological hyperexcitability.

Case description

Mr J.W., an 80-year-old man with a history of depression, was admitted to hospital with pneumonia. His condition deteriorated and he was sent to the intensive care unit (ICU) and placed on mechanical ventilation for several days. During his stay in the ICU, his medications were reviewed. His use of fluoxetine, which he’d taken for depression for almost 10 years, was discontinued. Following discharge from the ICU, his mood was noted to be low by the medical staff. Approximately 1 week after discontinuation of the fluoxetine, he started using 20 mg of paroxetine daily.
Within 24 hours of starting paroxetine, Mr J.W. was found to be confused and agitated with periods of unresponsiveness. Vital signs revealed a temperature of 38.5°C and a pulse of 115 beats per minute. A neurological examination revealed myoclonus in all limbs with any stimulation. Assessment by a family physician with training in care of the elderly identified serotonin syndrome as the probable cause of his presentation.
The paroxetine was discontinued and the patient was given intravenous fluids to decrease the risk of renal failure. Mr J.W. initially received 2 mg of lorazepam intravenously, then received 3, 1-mg doses of lorazepam every 4 hours, resulting in decreased tachycardia, hypertonicity, and clonus. He was discharged from hospital without antidepressants, and he planned to follow up with his family doctor several weeks after hospitalization in order to have his mood reviewed.

Discussion

Cochrane Database of Systematic Reviews, MEDLINE, and Google were searched from January 1990 to December 2006 for articles on serotonin syndrome or serotonin toxicity. Although there are research papers related to diagnosis, there are few high-quality data on prospective treatment. No guidelines or consensus statements have been published for either diagnosis or management. Recommendations were drawn from the literature, but there is minimal high-level evidence, especially in the realm of treatment. Most of the suggestions in this paper have level II evidence.

Serotonin (5-HT) was first identified in the 1940s and was initially thought to have its primary effect on vascular tone. Now serotonin is recognized as having an important role in several central nervous system processes and peripheral physiology, particularly in the gastrointestinal tract. The vast majority of serotonin (90%) is synthesized in the periphery, but brain serotonin levels are the main factor in development of serotonin toxicity.4

The main sites of serotonin production in the brain are the midline raphe nuclei, found in the brainstem from the midbrain to the medulla. In presynaptic neurons, the amino acid tryptophan is decarboxylated and hydroxylated to produce serotonin. Serotonin is released into the intrasynaptic space after axonal stimulation, and receptors on the presynaptic neuron play a role in regulating release. Following reuptake into the presynaptic neuron, intrasynaptic serotonin is metabolized by the enzyme monoamine oxidase.4 Knowledge of the regulation and metabolism of serotonin is relevant to understanding the role of different medications in the development of toxicity.

There are 7 serotonin receptor families (5-HT1 to 5-HT7), which are further subdivided into groups based on different activities in neural and peripheral organ systems. A summary of the effects of serotonin receptor subtypes in relation to serotonin toxicity is found in Table 1.4


View this table:
[in this window]
[in a new window]

  		Table 1 Effects of 5-HT receptor subtypes in relation to serotonin toxicity

 
Clinical presentation

The original and revised criteria5,6 for diagnosis of serotonin syndrome emphasize the mental status changes and clinical findings typically observed in more severe cases. As a result, these criteria have been criticized for not highlighting the wider spectrum of toxic side effects that can be seen with this disorder. For this reason, some authors prefer to use the term serotonin toxicity to include findings of earlier or milder cases.7

It is important to note that symptoms of serotonin syndrome usually present within 6 to 8 hours of initiating or increasing serotonergic medications.7,8 The onset tends to be more acute than in a condition such as neuroleptic malignant syndrome, which shares some other features with serotonin toxicity.

Serotonin syndrome usually manifests with autonomic changes, mental status changes, and neurological findings. Mild, moderate, and severe signs and symptoms of serotonin syndrome are summarized in Table 2.4 There are no data on the percentage of cases in the mild, moderate, or severe categories, in part because of the low rates of diagnosis of mild cases.


View this table:
[in this window]
[in a new window]

  		Table 2 Signs and symptoms of serotonin syndrome

 
Medication factor

Various medications are associated with serotonin syndrome.9–15 Medications that affect any of the steps in serotonin metabolism or regulation can provoke toxicity. Antidepressants, particularly selective serotonin reuptake inhibitors (SSRIs), are among the most commonly implicated drugs. Drug interactions can cause severe toxicity and can involve common over-the-counter medications. Drugs with long half-lives can interact several weeks after discontinuation; fluoxetine interactions have been reported up to 5 weeks after discontinuation.16 Even single doses of SSRIs have been implicated in serotonin syndrome. It is relevant to note that serotonin syndrome is not considered to be an idiosyncratic drug reaction but is a predictable response to elevated levels of serotonin.11 Table 39,11–15 provides a list of important drugs and drug interactions and the mechanism of increasing serotonin levels.


View this table:
[in this window]
[in a new window]

  		Table 3 Medications causing serotonin syndrome

 
Overdosing with single agents such as SSRIs does not often cause severe toxicity. Approximately 15% of SSRI overdoses result in moderate symptoms. Severe cases appear to be more likely after drug interactions, particularly monoamine oxidase inhibitors (MAOIs) interacting with other antidepressants or with serotonin releasers, such as amphetamines.11 Patient factors associated with developing toxicity are not clearly identified in the literature but might relate to factors affecting the pharmacokinetics of offending agents (eg, renal and hepatic failure). Patients who are genetically deficient in the cytochrome P450 2D6 enzyme (8% of whites) are more susceptible if they are taking drugs such as venlafaxine, paroxetine, tricyclics, dextromethorphan, and methadone.17

Diagnosis

A thorough history of current and recent medication use is important, as is ruling out the use of illicit drugs and dietary supplements. Clinicians should also consider pupil size and reactivity, skin colour, presence of diaphoresis, dryness of oral mucosa, and presence or absence of bowel sounds. Diagnosis is clinical and investigations are mostly done to identify sequelae of severe toxicity, including renal function, creatine kinase, myoglobin, and clotting parameters.18

As previously mentioned, the original criteria for diagnosing serotonin syndrome describe only severe cases. To help delineate the spectrum of illness, researchers in Australia reviewed more than 2000 cases of self-poisoning with serotonergic drugs and related the clinical findings to a diagnosis of serotonin syndrome made by a clinical toxicologist. From this information, a clinical decision tree was developed. This clinical approach has better sensitivity and specificity than older criteria (sensitivity 84%, specificity 97%).7 These decision rules are found in Table 4.7


View this table:
[in this window]
[in a new window]

  		Table 4 Decision rules for diagnosing serotonin syndrome in the presence of serotonergic agents within the past 5 weeks: Hunter serotonin toxicity criteria.

 
Several conditions should be considered when evaluating patients with confusion and neurological changes. Neuroleptic malignant syndrome (NMS) bears some resemblance to serotonin syndrome, with similar symptoms of fever, mental status changes, and altered muscle tone. However, patients with NMS are usually akinetic with rigidity, have decreased levels of consciousness, and are more likely to have mutism rather than rambling speech, which is associated with serotonin toxicity. More important, the onset of NMS is slow, developing over days rather than hours.19

One cause of delirium with neurological hyperexcitability is metabolite-mediated opiate toxicity, which can occur with rapid escalation of opioid doses, high opioid doses, or low opioid doses in patients with renal failure. Opiate toxicity is most likely caused by meperidine and morphine but can be seen with all opioid agents.20

Anticholinergic toxicity is differentiated by presence of skin colour changes (red as a beet), dry mouth (dry as a bone), and constipation or absence of bowel sounds .4,19

Treatment

Prompt recognition of toxicity and discontinuation of offending medications are most important. Many cases of the syndrome are self-limiting if medications are stopped early. The mortality of severe serotonin syndrome is estimated to range from 2% to 12%. The Toxic Exposure Surveillance System in the United States reported 93 deaths due to serotonin syndrome in 2002.1

Treatment is guided by the severity of presentation. There are currently no randomized placebo-controlled trials to guide pharmacologic treatment of serotonin syndrome, although case reports and series suggest several medications that are beneficial in managing the condition.

Supportive care, including intravenous fluids, is indicated in patients with vital sign abnormalities. Neurological symptoms, including serious myoclonus and hyperreflexia, are sometimes treated with benzodiazepines, but there is little evidence for this approach. Hyperthermia should be aggressively managed with external cooling, hydration, and benzodiazepines (eg, diazepam, lorazepam). Patients with a temperature higher than 41°C should be intubated with induced neuromuscular paralysis. There is a limited role for traditional antipyretics, as the mechanism of serotonin syndrome is due to muscle tone rather than central thermoregulation. Patient agitation secondary to delirium should be managed using nonpharmacologic strategies and benzodiazepines, when appropriate. Physical restraints should be avoided, as they can increase hyperthermia, lactic acidosis, and rhabdomyolysis (level II evidence).

The antihistamine cyproheptadine, which is also a 5-HT2A inhibitor, should be considered in moderate cases and is recommended in severe cases, despite a lack of randomized controlled trial evidence (level II evidence). It is available only as an oral preparation; the initial dose is 12 mg; the dosage is then adjusted to 2 mg every 2 hours until symptoms improve.21,22

Some antipsychotics have 5-HT2A antagonist effects and are sometimes used (level II evidence). Sublingual olanzapine and intramuscular chlorpromazine (50 to 100 mg) are options.23,24 Chlorpromazine can cause serious hypotension and should be avoided in severe cases with shock.

Caution is required in using antipsychotics for treating serotonin syndrome, as NMS can be misdiagnosed as serotonin syndrome. Also, case reports have implicated antipsychotics as precipitants of serotonin syndrome in individuals receiving concomitant serotonergic medications.1,25

Dantrolene, a skeletal muscle relaxant used for treatment of NMS, has been reported to improve symptoms of serotonin syndrome in a case series26; however, it has also been implicated in the development of serotonin toxicity and is not generally recommended.4,11 Propranolol, which has 5-HT1A antagonist activity and a long half-life, can potentiate hypotension and make improvement in tachycardia a less effective strategy for monitoring response to treatment.4,22

Mood management

No articles were found that assessed risk in depressed patients needing ongoing mood treatment after resolution of serotonin syndrome. Given that it is a predictable reaction, however, reinitiation after adequate washout should not result in increased risk, especially if an agent with less serotonergic activity is chosen (eg, bupropion, mirtazapine).10

All patients newly started on antidepressant medications should be assessed for suicidal thoughts. A recent Canadian study27 reviewed coroners’ reports of suicides and found that patients treated with SSRIs were 5 times more likely to have committed suicide within the first month of treatment than patients treated with other antidepressants. The absolute increase in risk was small (29/100 000 for SSRIs versus 6.2/100 000 for other anti-depressants). It is very important to note that patients who were not treated at all were at the highest risk.

This recommendation of increased monitoring of patients newly started on antidepressants is echoed in the guidelines on depression by the Canadian Coalition for Seniors’ Mental Health. These guidelines also suggest monitoring for serotonin-related side effects and suicidal thoughts early in treatment. Although a challenge in office practice, the guidelines suggest patients be seen weekly for at least several weeks after initiating treatment.28,29

Conclusion

Serotonin syndrome is increasingly common but not well recognized by physicians. Many medications can cause serotonin toxicity, and drug interactions are an important factor. Family physicians should consider the possibility of serotonin syndrome in patients taking serotonergic drugs who present with autonomic or mental status changes and neurological findings. The findings of clonus, ocular clonus, hyperreflexia, and hypertonicity should prompt evaluation and medication review. Treatment is based on severity and focuses on prompt cessation of offending agents, treatment of hyperthermia, and use of benzodiazepines to decrease hypertonicity and neurological excitability. The use of 5-HT antagonists should be considered in moderate and severe cases. Increased awareness and monitoring of patients beginning treatment with antidepressants can decrease the risk of worsening anxiety, agitation, and possibly suicide.

Levels of evidence

Level I: At least one properly conducted randomized controlled trial, systematic review, or meta-analysis

Level II: Other comparison trials, non-randomized, cohort, case-control, or epidemiologic studies, and preferably more than one study

Level III: Expert opinion or consensus statements


EDITOR’S KEY POINTS

  • Serotonin syndrome is not an idiosyncratic drug reaction, but a predictable response to elevated serotonin levels. Medications that affect any of the steps in serotonin metabolism or regulation can provoke toxicity.
  • Antidepressants are frequently implicated in serotonin syndrome. Interactions with other medications, such as common over-the-counter products (eg, dextromethorphan), can cause serious toxicity.
  • Symptoms can occur within 6 to 8 hours of initiating or increasing the dosage of serotonergic medications. Drugs with long half-lives can interact several weeks after discontinuation.
  • Treatment is based on the severity of the presentation. Many cases will be self-limited if the medications are stopped.

 


POINTS DE REPÈRE DU RÉDACTEUR

  • Le syndrome sérotoninergique n’est pas une réaction médicamenteuse idiosyncrasique, mais bien une réponse prévisible à des taux élevés de sérotonine. Les médicaments qui influencent l’une ou l’autre des étapes du métabolisme ou de la régulation de la sérotonine peuvent provoquer la toxicité.
  • Les antidépresseurs sont souvent en cause dans le syndrome sérotoninergique. Des interactions avec d’autres médicaments aussi courants que des produits en vente libre (p. ex. le dextrométhorphane) peuvent causer une sérieuse toxicité.
  • Les symptômes peuvent apparaître de 6 à 8 heures suivant l’amorce ou l’augmentation de la dose des médicaments influant sur la sérotonine. L’interaction des médicaments ayant une longue demi-vie peut se produire plusieurs semaines après leur discontinuation.
  • Le traitement dépend de la gravité des symptômes. Dans de nombreux cas, ils disparaissent d’euxmêmes si on arrête les médicaments.

 

Footnotes

Competing interests

None declared

Cet article a fait l’objet d’une revision par des pairs.

This article has been peer reviewed.

References

  1. Watson WA, Litovitz TL, Rodgers GC Jr, Klein-Schwartz W, Youniss J, Rose SR, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003;21(5):353–421.[Medline]
  2. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 1999;49(448):871–4.[Medline]
  3. Gillman PK. The spectrum concept of serotonin toxicity. Pain Med 2004;5(2):231–2.[Medline]
  4. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med 2005;352(11):1112–20. Erratum in: N Engl J Med 2005;356(23):2437.[Free Full Text]
  5. Radomski JW, Dursun SM, Reveley MA, Kutcher SP. An exploratory approach to the serotonin syndrome: an update of clinical phenomenology and revised diagnostic criteria. Med Hypotheses 2000;55(3):218–24.[Medline]
  6. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148(6):705–13.[Abstract/Free Full Text]
  7. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. QJM 2003;96(9):635–42.[Abstract/Free Full Text]
  8. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000;79(4):201–9.[Medline]
  9. Fugh-Berman A. Herbdrug interactions. Lancet 2000;355(9198):134–8. Erratum in: Lancet 2000;355(9208):1020.[Medline]
  10. Gillman PK. A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status. Hum Psychopharmacol 2006;21(2):117–25.[Medline]
  11. Gillman PK. A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biol Psychiatry 2006;59(11):1046–51. Epub 2006 Feb 7.[Medline]
  12. Hammerness P, Basch E, Ulbricht C, Barrette EP, Foppa I, Basch S, et al. St John’s wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics 2003;44(4):271–82.[Abstract/Free Full Text]
  13. Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004;42(3):277–85.[Medline]
  14. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis 2006;42(11):1578–83. Epub 2006 Apr 27.[Medline]
  15. Linde K, Mulrow CD, Berner M, Egger M. St John’s wort for depression. Cochrane Database Syst Rev 2005;(2):CD000448.
  16. Isbister GK, Dawson A, Whyte IM, Prior FH, Clancy C, Smith AJ. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Arch Dis Child Fetal Neonatal Ed 2001;85(2):F147–8.[Medline]
  17. Goldstein DB, Need AC, Singh R, Sisodiya SM. Potential genetic causes of heterogeneity of treatment effects. Am J Med 2007;120(4 Suppl 1):S21–5.[Medline]
  18. Rosebush PI, Garside S, Levinson A, Schroeder JA, Richards C, Mazurek M. Serotonin syndrome: a case series of 16 patients. Ann Neurol 2002;52(3S):S554.
  19. Pelonero AL, Levenson JL, Pandurangi AK. Neuroleptic malignant syndrome: a review. Psychiatr Serv 1998;49(9):1163–72.[Abstract/Free Full Text]
  20. Doyle D, Hanks G, Cherny NI, Calman KI. Oxford textbook of palliative medicine. 3 ed. New York, NY: Oxford University Press; 2003.
  21. Graudins A, Stearman A, Chan B. Treatment of the serotonin syndrome with cyproheptadine. J Emerg Med 1998;16(4):615–9.[Medline]
  22. McDaniel WW. Serotonin syndrome: early management with cyproheptadine. Ann Pharmacother 2001;35(7–8):870–3.[Abstract]
  23. Gillman PK. The serotonin syndrome and its treatment. J Psychopharmacol 1999;13(1):100–9.[Abstract/Free Full Text]
  24. Boddy R, Ali R, Dowsett R. Use of sublingual olanzapine in serotonin syndrome. J Toxicol Clin Toxicol 2004;42(5):725.
  25. Duggal HS, Fetchko J. Serotonin syndrome and atypical antipsychotics. Am J Psychiatry 2002;159(4):672–3.[Free Full Text]
  26. Nisijima K, Ishiguro T. Does dantrolene influence central dopamine and serotonin metabolism in the neuroleptic malignant syndrome? A retrospective study. Biol Psychiatry 1993;33(1):45–8.[Medline]
  27. Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006;163(5):813–21.[Abstract/Free Full Text]
  28. Canadian Coalition for Seniors’ Mental Health. Canadian Coalition for Seniors’ Mental Health guidelines on depression. Toronto, ON: Canadian Coalition for Seniors’ Mental Health; 2006. Available from: www.ccsmh.ca. Accessed 2008 Jun 9.
  29. Buchanan D, Tourigny-Rivard MF, Cappeliez P, Frank C, Janikowski P, Spanjevic L, et al. National guidelines for seniors’ mental health: the assessment and treatment of depression. Can J Ger 2006;9(S2):S52–8.




This Article
Right arrow Full Text (PDF)
Right arrow Rapid Responses: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Frank, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Frank, C.

HOME HELP CONTACT US FEEDBACK SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES SEARCH